Is Trending Stock Amgen Inc. (AMGN) a Buy Now?

Amgen (AMGN) has recently underperformed the broader market and its industry, returning -2.4% over the past month, despite a history of consistently beating earnings and revenue estimates. While current quarter EPS is projected to decline 8.6% year-over-year with recent negative revisions, full-year EPS and revenue estimates remain positive. The stock carries a Zacks Rank #3 (Hold), implying near-term performance in line with the market, and its 'B' Zacks Value Style Score suggests it is currently trading at a discount to peers.

Analysis

Amgen (AMGN) presents a mixed fundamental picture, characterized by recent stock underperformance against a backdrop of conflicting earnings signals. Over the past month, the stock has declined 2.4%, lagging both the S&P 500's 2.7% gain and its industry's 1.8% rise. This weakness coincides with a challenging near-term earnings outlook; consensus estimates for the current quarter project an 8.6% year-over-year EPS decline, and these estimates have been revised downward by 5.2% in the last 30 days. However, looking at the full fiscal year, the outlook is more constructive, with analysts forecasting 6.2% EPS growth and 6.6% revenue growth, supported by modest positive revisions. This growth is expected to decelerate significantly in the next fiscal year to 1.8% for EPS and 1.5% for revenue. Despite the near-term headwinds, Amgen has a strong track record of execution, having beaten EPS estimates in the last four quarters and revenue estimates in three of those. Furthermore, with a Zacks Value Style Score of 'B', the stock appears to be trading at a discount relative to its peers, a factor that is balanced against the neutral Zacks Rank #3 (Hold) which suggests near-term performance in line with the broader market.

Key Decisions for Investors

• Given the conflicting signals of a near-term earnings decline versus positive full-year growth, a neutral stance is warranted, aligning with the Zacks #3 'Hold' rating until the next earnings report clarifies the company's trajectory.
• Value-oriented investors may find the stock's recent underperformance and its 'B' grade for value an attractive entry point, provided they can look past the current quarter's projected weakness.
• Investors focused on growth should be cautious of the significant deceleration in forecasted revenue and EPS growth for the next fiscal year, which could cap the stock's upside potential.